Kimberly D Allman

631 total citations
31 papers, 473 citations indexed

About

Kimberly D Allman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Kimberly D Allman has authored 31 papers receiving a total of 473 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Kimberly D Allman's work include Renal cell carcinoma treatment (22 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Cancer Genomics and Diagnostics (10 papers). Kimberly D Allman is often cited by papers focused on Renal cell carcinoma treatment (22 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Cancer Genomics and Diagnostics (10 papers). Kimberly D Allman collaborates with scholars based in United States, India and United Kingdom. Kimberly D Allman's co-authors include Brian I. Rini, Moshe Chaim Ornstein, Jorge A. García, Laura S. Wood, Timothy D. Gilligan, Allison Martin, Petros Grivas, Hans J. Hammers, Pedro C. Barata and Brian P. Hobbs and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Kimberly D Allman

30 papers receiving 469 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kimberly D Allman United States	11	372	269	177	169	74	31	473
Gunta Purkalne Latvia	12	119 0.3×	183 0.7×	151 0.9×	129 0.8×	49 0.7×	31	425
John A. Steinharter United States	13	431 1.2×	541 2.0×	231 1.3×	161 1.0×	134 1.8×	30	778
R. Gulati United States	2	454 1.2×	230 0.9×	99 0.6×	86 0.5×	104 1.4×	4	617
Marek Ziobro Poland	11	267 0.7×	277 1.0×	196 1.1×	130 0.8×	58 0.8×	46	457
C. Le Tourneau France	12	142 0.4×	213 0.8×	108 0.6×	72 0.4×	47 0.6×	41	399
Christoph Minichsdorfer Austria	13	119 0.3×	142 0.5×	198 1.1×	172 1.0×	64 0.9×	33	428
Shivanshu Awasthi United States	10	231 0.6×	142 0.5×	79 0.4×	91 0.5×	28 0.4×	27	353
Aditi P. Singh United States	12	208 0.6×	204 0.8×	59 0.3×	147 0.9×	31 0.4×	41	358
Jean-François Caubet United States	6	255 0.7×	200 0.7×	114 0.6×	44 0.3×	51 0.7×	8	473
Hernán Carranza Colombia	10	280 0.8×	245 0.9×	131 0.7×	117 0.7×	28 0.4×	36	417

Countries citing papers authored by Kimberly D Allman

Since Specialization

Citations

This map shows the geographic impact of Kimberly D Allman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly D Allman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly D Allman more than expected).

Fields of papers citing papers by Kimberly D Allman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly D Allman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly D Allman. The network helps show where Kimberly D Allman may publish in the future.

Co-authorship network of co-authors of Kimberly D Allman

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly D Allman. A scholar is included among the top collaborators of Kimberly D Allman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly D Allman. Kimberly D Allman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barata, Pedro C., Alex Chehrazi‐Raffle, Kimberly D Allman, et al.. (2023). Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial. The Oncologist. 28(10). 894–900. 2 indexed citations

Desai, Kunal, Lisa Rybicki, Amanda Nizam, et al.. (2020). Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I+N).. Journal of Clinical Oncology. 38(15_suppl). e17094–e17094. 1 indexed citations

Fallah, Jaleh, Ruby Gupta, Hong Li, et al.. (2020). Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. Targeted Oncology. 15(4). 477–483. 5 indexed citations

Allman, Kimberly D, et al.. (2019). Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario. Journal of the Advanced Practitioner in Oncology. 10(5). 483–493. 1 indexed citations

Ornstein, Moshe Chaim, Cassandra Calabrese, Laura S. Wood, et al.. (2019). Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer. 17(3). 177–182. 9 indexed citations

Gupta, Ruby, Moshe Chaim Ornstein, Hong Li, et al.. (2019). Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non–Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer. 18(6). 429–435. 53 indexed citations

Ornstein, Moshe Chaim, Sumanta K. Pal, Laura S. Wood, et al.. (2019). Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. The Lancet Oncology. 20(10). 1386–1394. 78 indexed citations

Ornstein, Moshe Chaim, Laura S. Wood, Brian P. Hobbs, et al.. (2019). A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy. Journal for ImmunoTherapy of Cancer. 7(1). 127–127. 24 indexed citations

Gupta, Ruby, Moshe Chaim Ornstein, Kimberly D Allman, et al.. (2019). Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).. Journal of Clinical Oncology. 37(15_suppl). e16084–e16084. 6 indexed citations

10.

Barata, Pedro C., Alfonso Gómez de Liaño, Prateek Mendiratta, et al.. (2018). Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens.. Journal of Clinical Oncology. 36(6_suppl). 613–613. 6 indexed citations

11.

Ornstein, Moshe Chaim, Sumanta K. Pal, Laura S. Wood, et al.. (2018). Prospective phase II multi-center study of individualized axitinib (Axi) titration for metastatic renal cell carcinoma (mRCC) after treatment with PD-1 / PD-L1 inhibitors.. Journal of Clinical Oncology. 36(15_suppl). 4517–4517. 11 indexed citations

12.

Barata, Pedro C., Vadim S. Koshkin, Prateek Mendiratta, et al.. (2018). Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. Targeted Oncology. 13(3). 353–361. 10 indexed citations

13.

Zahoor, Haris, Pedro C. Barata, Xuefei Jia, et al.. (2018). Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. Journal for ImmunoTherapy of Cancer. 6(1). 107–107. 51 indexed citations

14.

Ornstein, Moshe Chaim, Andrew J. Stephenson, Paul Elson, et al.. (2018). Adjuvant enzalutamide (Enza) for men with non-metastatic high-risk prostate cancer (HRPCa) after radical prostatectomy (RP).. Journal of Clinical Oncology. 36(6_suppl). 88–88. 3 indexed citations

15.

Chen, Yu‐Wei, Moshe Chaim Ornstein, Laura S. Wood, et al.. (2018). The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. Urologic Oncology Seminars and Original Investigations. 36(10). 470.e19–470.e29. 4 indexed citations

16.

Koshkin, Vadim S., Pedro C. Barata, Haris Zahoor, et al.. (2017). Cisplatin-based neoadjuvant chemotherapy (NAC) in bladder cancer patients (Pts) with borderline renal function: Implications for clinical practice.. Journal of Clinical Oncology. 35(6_suppl). 390–390. 1 indexed citations

17.

Ornstein, Moshe Chaim, Laura S. Wood, Paul Elson, et al.. (2017). A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 35(16). 1764–1769. 32 indexed citations

18.

Ornstein, Moshe Chaim, Laura S. Wood, Paul Elson, et al.. (2016). Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 15(2). e275–e280. 20 indexed citations

19.

Ornstein, Moshe Chaim, Paul Elson, Jorge A. García, et al.. (2015). Clinical effect of TKI dose-escalation after disease progression in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 33(15_suppl). 4562–4562. 2 indexed citations

20.

Sunwoo, John B., et al.. (1995). School-based AIDS education for adolescents. Journal of Adolescent Health. 16(4). 309–315. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact